Baxter International and Water Street Healthcare have received approval from the US Food and Drug Administration (FDA) for Cefazolin Injection in Galaxy container (2g/100ml).
Cefazolin Injection is a cephalosporin antibacterial suggested for preoperative prophylaxis treatment.
Go deeper with GlobalData
Baxter hospital products business president Brik Eyre said: "The availability of Cefazolin 2g in an efficient, ready-to-use, flexible, premix container that can improve pharmacy efficiency will provide additional supply options of an important antibiotic.
"Baxter’s innovative development partnership with Water Street allows us to accelerate product development and offers healthcare providers additional options for critical care medications produced with our proprietary manufacturing capabilities and in our container technology."
Cefazolin Injection 2gm is the first of nine molecules Baxter developed under a partnership with Celerity Pharmaceuticals, a company of Water Street.
The firm plans to introduce Cefazolin 2g frozen premix in its Galaxy container in the US during the fourth quarter of this year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCefazolin Injection must be used only to prevent infections that are proven or strongly suspected to be caused by bacteria, in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of the treatment.
According to the firm, clostridium difficile associated diarrhoea (CDAD) has been reported with Cefazolin Injection and may range in severity from mild diarrhoea to fatal colitis.
Baxter offers a wide range of essential renal and hospital products, including home, acute and in-centre dialysis, infusion systems and devices, parenteral nutrition, and biosurgery products and anaesthetics.
